 SHELTON, CT ACCESSWIRE June 9, 2020 NanoViricides, Inc. NYSE American:NNVC the Company a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reported today that it has signed a Memorandum of Understanding MoU with respect to anti-viral treatments for coronavirus derived human infections the Field with TheraCour Pharma, Inc. The MoU specifically provides a limited, exclusive license to all research and development in the Field for further research and development purposes towards human clinical trials. NanoViricides intends to retain an independent consultant for the evaluation of the assets in order to develop the full license agreement. 